Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab

Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ava Diarra, Guillaume Gantois, Mouna Lazrek, Basile Verdier, Vincent Elsermans, Hélène Zephir, Benjamin Longère, Xristos Gkizas, Céline Goeminne, Gilles Lemesle, Francis Juthier, Johana Bene, David Launay, Romain Dubois, Sandrine Morell-Dubois, Fanny Vuotto, Anne-Laure Piton
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/68801583d27f4893b4862bf8364564d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:68801583d27f4893b4862bf8364564d6
record_format	dspace
spelling	oai:doaj.org-article:68801583d27f4893b4862bf8364564d62021-12-04T16:04:26ZFatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab10.15420/cfr.2020.332057-75592057-7540https://doaj.org/article/68801583d27f4893b4862bf8364564d62021-05-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2020.33https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.Ava DiarraGuillaume GantoisMouna LazrekBasile VerdierVincent ElsermansHélène ZephirBenjamin LongèreXristos GkizasCéline GoeminneGilles LemesleFrancis JuthierJohana BeneDavid LaunayRomain DuboisSandrine Morell-DuboisFanny VuottoAnne-Laure PitonRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 7, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ava Diarra Guillaume Gantois Mouna Lazrek Basile Verdier Vincent Elsermans Hélène Zephir Benjamin Longère Xristos Gkizas Céline Goeminne Gilles Lemesle Francis Juthier Johana Bene David Launay Romain Dubois Sandrine Morell-Dubois Fanny Vuotto Anne-Laure Piton Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
description	Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
format	article
author	Ava Diarra Guillaume Gantois Mouna Lazrek Basile Verdier Vincent Elsermans Hélène Zephir Benjamin Longère Xristos Gkizas Céline Goeminne Gilles Lemesle Francis Juthier Johana Bene David Launay Romain Dubois Sandrine Morell-Dubois Fanny Vuotto Anne-Laure Piton
author_facet	Ava Diarra Guillaume Gantois Mouna Lazrek Basile Verdier Vincent Elsermans Hélène Zephir Benjamin Longère Xristos Gkizas Céline Goeminne Gilles Lemesle Francis Juthier Johana Bene David Launay Romain Dubois Sandrine Morell-Dubois Fanny Vuotto Anne-Laure Piton
author_sort	Ava Diarra
title	Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
title_short	Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
title_full	Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
title_fullStr	Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
title_full_unstemmed	Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
title_sort	fatal enterovirus-related myocarditis in a patient with devic’s syndrome treated with rituximab
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/68801583d27f4893b4862bf8364564d6
work_keys_str_mv	AT avadiarra fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT guillaumegantois fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT mounalazrek fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT basileverdier fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT vincentelsermans fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT helenezephir fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT benjaminlongere fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT xristosgkizas fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT celinegoeminne fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT gilleslemesle fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT francisjuthier fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT johanabene fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT davidlaunay fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT romaindubois fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT sandrinemorelldubois fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT fannyvuotto fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab AT annelaurepiton fatalenterovirusrelatedmyocarditisinapatientwithdevicssyndrometreatedwithrituximab
_version_	1718372678980599808

Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab

Ejemplares similares